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Abstract
Background: Accelerated partial breast irradiation (APBI) is a new breast treatment modality aiming to reduce
treatment time using hypo fractionation. Compared to conventional whole breast irradiation that takes 5 to 6 weeks,
APBI is reported to induce worse cosmetic outcomes both when using three-dimensional conformal radiotherapy
(3D-CRT) and intensity-modulated radiotherapy (IMRT). These late normal tissue effects may be attributed to the
dose volume effect because a large portion of the non-target breast tissue volume (NTBTV) receives a high dose.
In the context of APBI, non-coplanar beams could spare the NTBTV more efficiently. This study evaluates the
dosimetric benefit of using the Cyberknife (CK) for APBI in comparison to IMRT (Tomotherapy) and three
dimensional conformal radiotherapy (3D-CRT).
Methods: The possibility of using surgical clips, implanted during surgery, to track target movements is investigated
first. A phantom of a female thorax was designed in-house using the measurements of 20 patients. Surgical clips of
different sizes were inserted inside the breast. A treatment plan was delivered to the mobile and immobile phantom.
The motion compensation accuracy was evaluated using three radiochromic films inserted inside the breast. Three
dimensional conformal radiotherapy (3D-CRT), Tomotherapy (TOMO) and CK treatment plans were calculated for 10
consecutive patients who received APBI in Lille. To ensure a fair comparison of the three techniques, margins applied
to the CTV were set to 10 mm. However, a second CK plan was prepared using 3 mm margins to evaluate the benefits
of motion compensation.
Results: Only the larger clips (VITALITEC Medium-Large) could be tracked inside the larger breast (all gamma indices
below 1 for 1 % of the maximum dose and 1 mm). All techniques meet the guidelines defined in the NSABP/RTOG
and SHARE protocols. As the applied dose volume constraints are very strong, insignificant dosimetric differences exist
between techniques regarding the PTV coverage and the sparing of the lung and heart. However, the CK may be used
to reduce high doses received by the NTBTV more efficiently.
Conclusions: Robotic stereotactic radiotherapy may be used for APBI to more efficiently spare the NTBTV and improve
cosmetic results of APBI.
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Introduction
Breast cancer is the most common cancer in women,
representing approximately 25 % of all cancers in
women [1]. Conventional treatments range from surgery
to radiotherapy of the whole breast. The recommended
dose for the whole breast varies between 40 and 50 Gy
delivered in 3 to 5 weeks followed by 16 Gy to the resec-
tion margins in younger women. Accelerated partial
breast irradiation (APBI) is a new treatment modality
aiming to reduce treatment time using fraction doses
higher than conventional fractionation. The total dose is
between 38 and 40 Gy in 10 fractions delivered in 5
days. As opposed to whole breast irradiation (WBI), the
dose is given only to the resection volume. Multiple
techniques have been tried, including intraoperative
radiotherapy, brachytherapy and conformal radiotherapy.
APBI using conformal radiotherapy is investigated in
several randomized studies around the world, including
a French multicenter phase III trial. Prescribed doses
are identical in RTOG and French trials (NSABP/
RTOG protocol, SHARE protocol [2]). Cosmetic results
after APBI seem controversial [3]. Worse cosmetic out-
comes have been reported using three-dimensional
conformal radiotherapy (3D-CRT) [4] as well as
intensity-modulated radiotherapy (IMRT) [5] for APBI.
In a randomized trial, 3D-CRT APBI increased rates of
adverse cosmesis and late radiation toxicity compared
with standard WBI [6]. These late normal tissue effects
may be attributed to the dose volume effect [7] because
a large portion of the non-target breast tissue volume
(NTBTV) receives a high dose.
The CyberKnife (Accuray Incorporated, Sunnyvale
CA, USA) [8, 9] is a frameless robotic radiosurgery sys-
tem. In the context of APBI, the Cyberknife could spare
the NTBTV more efficiently because of the combination
of non-coplanar fields and tracking of the target volume.
In a publication from Vermeulen et al. [10], excellent/
good cosmetic outcomes were described after a follow-
up period of 12 months for 9 patients who received
APBI using the CyberKnife. A dosimetric investigation
of APBI using the CyberKnife suggests the same results
[11]. Our study proposes to investigate the effect of non-
coplanar beams for APBI. This effect is first evaluated
comparing Cyberknife, IMRT (Tomotherapy) and 3D-
CRT treatment plans calculated for 10 patients using the
same PTV margins. The feasibility and benefit of track-
ing the target volume are evaluated in a second part.
Synchrony, the respiratory tracking system provided
with the Cyberknife, uses diagnostic x-ray images of
fiducials implanted in the target volume to correlate the
position of the target volume to the position of external
markers. This model enables the linear accelerator to
continuously track the motion of the target volume re-
garding the position of external markers. The possibility
of using surgical clips that are implanted during surgery
to track target movements is investigated here to avoid
an additional invasive procedure. The benefit of tracking
using the Cyberknife is evaluated at last and a Cyber-




Ten consecutive patients were selected for this study.
This study was approved by the scientific board of the
multidisciplinary breast tumor institutional group. These
patients received 3D-CRT APBI in the Oscar Lambret
Cancer Center in Lille, France between December 2010
and October 2012. A radiotherapy treatment planning
CT was acquired for each patient. Patients were posi-
tioned in the supine position using a breast board. The
CT started at or above the mandible and extended sev-
eral centimeters below the inferior limit of the breast.
According to our 3D-CRT protocol, the pixel size was
set to 1 mm in the transverse plane and 3 mm in the
longitudinal direction. The target and organs at risk
delineation were realized according to SHARE and
NSABP/RTOG 0413 guidelines. The following structures
were contoured: CTV, NTBTV, contralateral breast,
heart, homolateral lung and contralateral lung. Volume
expansion was limited to exclude pectoralis muscles, the
chest wall and the first 3 mm beneath the skin.
Three radiotherapy treatment plans were calculated
for each patient using 10 mm margins between the CTV
and PTV: 3D-CRT, Tomotherapy (TOMO) and Cyber-
Knife (CK). TOMO and CK plans were only computed
for technique comparison purposes and may not be rele-
vant for treatment. A second Cyberknife plan was com-
puted using 3 mm PTV margin (CKRM) to take into
account the motion compensation abilities of the Cyber-
Knife (Synchrony). 3 mm is the margin used in our
institution for synchrony liver treatments. The 3D-CRT
plans were designed using ONCENTRA MASTERPLAN
(Elekta Inc., Stockholm, Sweden). Three beams were pri-
marily used: two tangential photon beams (6 or 20 MV
depending on size and shape of the breast) and a direct
electron beam whose energy depends on the depth of
the tumor. A dose of 40 Gy was prescribed to the PTV,
with 39 Gy covering at least 95 % of the PTV. Dose cal-
culations were made using the collapsed cone algorithm
and a 3 mm dose grid. Tomotherapy plans were calcu-
lated using a Tomotherapy planning station (version
4.2). A directional block was used to prevent the use of
opposed beams. The final dose was calculated using the
convolution/superposition algorithm based on the col-
lapsed cone approach [12] in fine resolution (pixel size
of 1 mm). CyberKnife plans were optimized using both
Multiplan (CyberKnife planning system version 4.6.0)
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and the dynamic collimator (IRIS). Collimator sizes were
adapted to the target volume to optimize conformality
while maintaining reasonable treatment times (40 min).
Final dosimetric calculations were computed using the
Monte Carlo algorithm in a 2 mm dose grid and a statis-
tical uncertainty of 2 %. All plans satisfy the constraints
(Table 1) defined in the SHARE and NSABP/RTOG
protocols. In the case conflicting constraints, the most
restrictive one was chosen.
B. Dosimetric parameters for plan comparison
For each treatment plan, the mean dose delivered to
2 % (D2%) and 98 % (D98%) of the PTV were re-
ported. The homogeneity index (HI) and the Dice
similarity coefficient (DSC) were calculated using the
definitions from ICRU report 83 [13]. The homogen-
eity index is defined as:
HI ¼ D2%−D98%
D50%
The Dice similarity index is defined as the ratio of the
intersection between the treated volume (TV) and the
PTV over the sum of these volumes:
DSC ¼ 2  TV∩PTVð Þ
TV þ PTV
Following the recommendations from ICRU report 86,
the target volume is defined as the volume receiving at
least 98 % of the maximum dose.
Doses delivered to the OAR were compared using
dose volume histograms (DVH) and organ specific dosi-
metric data: the mean dose (Dmean), the near-maximum
dose (D2%), the volumes receiving 18 (V18Gy) and 20 Gy
(V20Gy) for the NTBTV, the volumes receiving 5 (V5Gy),
10 (V10Gy) and 20 Gy (V20Gy) for the homolateral lung,
the volumes receiving 2 (V2Gy) and 5 Gy (V5Gy) for the
heart and the near-maximum dose (D2%) for the contra-
lateral breast. The dose delivered to the heart was calcu-
lated only in the five patients with left-sided breast
cancer. In this study, we compared the CyberKnife to
other techniques; we did not compare these techniques
with each other. Significant differences between tech-
niques were enhanced using the Wilcoxon signed-rank
test (significance threshold p < 0.05).
C. Surgical clip tracking
Using Synchrony to track respiratory motions could re-
duce PTV margins from 10 to 3 mm and thus reduce
the dose delivered to the NTBTV. However, fiducial
markers are required to follow target volume move-
ments inside the patient. Implantation of fiducial
markers is an additional invasive act for a patient. Titan-
ium surgical clips are used in our institution to delineate
the excision volume after surgery. If these clips would be
visible for the tracking system of the CyberKnife, the im-
plantation of fiducial markers would no longer be
required.
A realistic breast phantom was designed to study sur-
gical clip tracking. The new phantom can be used in
combination with the Xsight lung thorax (CIRS Inc.,
Norfolk, USA) phantom proposed for the CyberKnife.
As shown in Fig. 1a, breast size was measured in the
middle of the breast between the skin and the chest wall
for 30 consecutive patients treated for breast cancer.
Two breast sizes were used: the medium size (55.4 mm)
for the right breast and the largest size (106 mm) for the
left breast. Figure 1b shows the breast phantom positioned
on top of the Xsight lung phantom. The phantom geom-
etry was described using two ellipses (Fig. 1c and d).
The breast phantom is made of natural polyethylene
(0.97 g.cm−3) and composed of 10 slices (5 external
slices of 20-mm width and 5 central slices of 10-mm
width). This material is similar to breast tissues in
the energy range of photons used for diagnostic radi-
ology. Radiochromic films were inserted between the
slices of the phantom to record the dose distribution.
All radiochromic films were taken from the same
batch. This batch was calibrated in dose response a
week before the experiments using the red and blue
channels. Exposed films were scanned 14 h after
Table 1 Constraints given by the SHARE and NSABP/RTOG
protocols used to optimize all treatment plans
PTV Dmax < 44 Gy
D99%≥ 38Gy
D95% ou D90%≥ 40 Gy
Homolateral lung V20Gy < 1.3 %
V12Gy < 15 %
V10Gy < 5.7 %
V5Gy < 8 %
Contralateral lung V20Gy < 1 %
V10Gy < 2 %
V5Gy < 3 %
V2Gy < 15 %
Heart V20Gy < 0.5 %
V10Gy < 1 %
V5Gy < 4.1 %
V2Gy < 5 % for left lesions
V2Gy < 40 % for right lesions
Contralateral breast Dmax < 3 % of prescribed dose (Dmax < 1.3 Gy)
NTBV V20Gy < 50 %
V18Gy <60 %
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irradiation at 72 dpi in 48-bit RGB transmission mode
on an Epson Expression 10000 XL.
Three titanium surgical clips of different sizes were
tested: VITALITEC 6 Small-Medium (Vitalitec Inter-
national, Inc., Plymouth, USA), LIGACLIP EXTRA
medium (ETHICON Inc., Cornelia, USA) and VITALI-
TEC Medium-Large. Four cavities were bored inside the
phantom in each breast to insert the clips. A CyberKnife
treatment plan was created to deliver 3.8 Gy in an ir-
regular volume surrounding the clips. Clips of each size
were inserted inside the phantom, and the treatment
plan was delivered to both an immobile and mobile
phantom (with and without Synchrony). In each case,
three Gafchromic films were inserted inside the phan-
tom (central slices containing the clips) to record the
dose distribution in three parallel plans. Phantom move-
ment was longitudinal with frequencies and amplitudes
(3 cm) close to the values of human breathing [14, 15].
The gamma index [16] was chosen to quantify the
agreement between dose distributions measured with or
without Synchrony and the dose distributions measured
without any movement of the phantom (gold standard).
Gamma indices were calculated using an in-house
Matlab routine. Films were registered using three points
corresponding to spatial markers at the surface of the
breast phantom and drawn on the Gafchromic films.
Gamma index limits were set to 1 mm, 1 % (3 Cgy)
corresponding to the best results we could obtain.
Results
A. Surgical clip tracking
Only the larger clips (VITALITEC Medium-Large)
could be tracked using Synchrony inside the left
breast (larger breast, worst case scenario). The dose
distributions displayed in Fig. 2 are measured using
Gafchromic EBT3 films inside the left breast. Only
gamma indices calculated inside the breast were con-
sidered. The results show that dose distributions
agree very well when Synchrony is used for respira-
tory motion compensation (all gamma indices below
1 for 1 mm and 3 cGy).
B. Dosimetric comparison
Table 2 shows mean dosimetric data computed for each
treatment modality. Significant differences between
CKRM and the other techniques are highlighted in bold
font (p-values < 0.05). Corresponding mean DVHs are
displayed in Fig. 3 for all treatment modalities.
For PTV coverage, the DVHs displayed in Fig. 3a for
all treatment modalities are very close. The mean HI is
between 0.132 (3D) and 0.0097 (TOMO) and the mean
DSC is between 0.769 (TOMO) and 0.858 Gy (CKRM).
PTV near-min doses (D98%) range from 37.5 (3D-CRT)
to 39.0 (CKRM) and near-maximum doses range from
43.1 (3D-CRT) to 44.1 Gy (CK and CKRM) (p > 0.05).
As shown in Fig. 3b, DVHs of the NTBTV show sig-
nificant differences between techniques. The use of non-
coplanar beams (CK and CKRM) reduces high doses to
the NTBTV. Significant differences were found between
CKRM and all other techniques for the near-maximum
dose (D2%) and the volume receiving 20 Gy (V20Gy) of
the NTBTV. Mean doses to the NTBTV vary from 17.3
(TOMO) to 9.9 Gy (CKRM). V18Gy ranges from 20.7
(CKRM) to 45.5 % (TOMO) (Table 2).
Dosimetric data are very close for the homolateral
lung, heart and contralateral breast. These results are
displayed using DVHs in Fig. 3c, d and e. Significant
Fig. 1 Breast phantom: thickness of the breast measured between the chest wall and the skin on 30 patients’ CT (a), breast phantom geometry
with two breasts of different dimensions (c and d) and breast phantom positioned on the Xsight lung phantom (b)
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Fig. 2 Dose distributions measured inside the left breast for an immobile (a) and a mobile phantom with (b) or without (c) motion compensation.
Dose profiles recorded along the white dotted line drawn on figure a are displayed on the left bottom side of the figure
Table 2 Comparison of PTV, heart, lung and NTBTV dosimetric data for 3D-CRT, tomotherapy (TOMO), CyberKnife (CK) and Cyber-
Knife with reduced margins (CKRM). CKRM data are written in bold letters when there are significant differences between CKRM and
at least one other technique (only p-values < 0.05 are specified)
3D-CRT TOMO CK CKRM P value CK-RM vs RC3D P value CK-RM vs TM P value CK-RM vs CK
PTV
HI 0.132 ± 0.079 0.097 ± 0.016 0.123 ± 0.01 0.121 ± 0.01
DSC 0.805 ± 0.047 0.769 ± 0.053 0.850 ± 0.04 0.858 ± 0.03
D98% (Gy)D2% (Gy) 37.5 ± 3.1 39.8 ± 0.5 38.9 ± 0.9 39.0 ± 0.3
43.1 ± 0.5 43.8 ± 0.4 44.1 ± 1.1 44.1 ± 0.3
NTBTV
Dmean (Gy) 11.3 ± 3.7 17.3 ± 4.0 12.3 ± 3.0 9.9 ± 2.0 0.002 0.002
D2% (Gy) 40.5 ± 1.2 40.3 ± 1.2 39.4 ± 1.5 34.6 ± 2.6 0.0020 0.002 0.002
V18Gy (%) 28.6 ± 10.2 45.5 ± 12.5 26.4 ± 8.2 20.7 ± 7.1 0.002 0.0039
V20Gy (%) 27.7 ± 10.1 41.3 ± 12.1 23.3 ± 7.8 17.6 ± 6.5 0.0195 0.0059 0.0039
Homolateral Lung
V5Gy (%) 6.2 ± 2.3 6.6 ± 3.1 9.8 ± 9.5 3.8 ± 6.1 0.002
V10Gy (%) 1.2 ± 0.5 2.3 ± 1.6 2.0 ± 2.9 0.7 ± 1.5 0.0059 0.002
V20Gy (%) 0.2 ± 0.2 0.3 ± 0.5 0.2 ± 0.4 0.0 0.0078 0.0156 0.0312
Heart
V2Gy (%) 4.7 ± 3.4 2.2 ± 3.1 7.5 ± 6.7 3.9 ± 7.6
V5Gy (%) 0.2 ± 0.4 0.0 ± 0.0 0.3 ± 0.7 0.0 ± 0.0
Contralateral Breast
D2% (Gy) 0.3 ± 0.2 1.7 ± 1.0 1.3 ± 2.0 1.3 ± 1.8
PTV planning target volume, NTBTV non-target breast tissue volume, 3D-CRT three-dimensional conformal radiotherapy
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differences were found for the volume of homolateral
lung receiving 20 Gy (V20Gy). Values range from
0.0 Gy for CKRM to 0.3 Gy for TOMO.
Discussion
In the literature, cosmetic results of APBI remain
controversial. The interim NSABP B-39/RTOG 0413
Fig. 3 Mean DVH data for PTV (a), NTBTV (b), homolateral lung (c), heart (d) and contralateral breast (e). PTV: planning target volume; NTBTV:
non-target breast tissue volume. 3D: 3D-conformal radiation therapy, TM: Tomotherapy, CK: CyberKnife, CKRM: CyberKnife with reduced margins
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randomized trial report showed a low and acceptable
toxicity rate [17]. Some adverse cosmetic effects may be
attributed to the dose volume effect because a large por-
tion of the NTBTV receives a high dose [7]. In Leonard
et al. [18], the relative volume of breast tissue receiving
5 to 100 % (V5-V100) of the prescribed dose was associ-
ated with a risk of subcutaneous fibrosis, and the volume
receiving 50 to 100 % (V50-V100) was associated with
fair/poor cosmesis in 80 patients. In a Moffitt Cancer
Center series of 94 patients who were treated according
to RTOG 0413 guidelines, increasing the percentage of
ipsilateral breast volume receiving more than 50 % of
the prescription dose (V50%) was correlated with less
than excellent cosmesis (p < 0.001) with a threshold V50%
of 40 % [19]. In Olivotto et al. [6], APBI increased rates
of adverse cosmesis and late radiation toxicity compared
with standard WBI in a randomized trial. Nevertheless,
the high-dose treatment volume was not independently
associated with an adverse cosmetic outcome. On fur-
ther exploration, a V95%/whole-breast volume ratio <0.15
was associated with a lower risk of cosmetic deterior-
ation (p = 0.04), but this accounted for a small number
of the patients [20]. Although literature data seem
contradictory, it seems important to preserve NTBTV as
much as possible.
PTV coverage is equivalent for all treatment modalities
as doses received by the homolateral lung, heart and
contralateral breast. These results arise from the con-
straints imposed by the SHARE and NSABP protocols
(Table 1). As displayed in Table 2 and Fig. 3b, the main
differences between the techniques are located in the
NTBTV. Non-coplanar beams may be used to reduce
the proportion of NTBTV that receives high doses. It is
however very unlikely that we would treat a patient
using spine tracking. Using fiducials implanted inside
the target volume, the CyberKnife is able to correlate the
target movements to the respiratory cycle. It is thus pos-
sible to reduce PTV margins to 3 mm instead of the
10 mm that is observed without motion tracking. Using
3 mm margins, the proportion of NTBTV receiving high
doses is further reduced. Differences in homolateral lung
doses seem too small to be of clinical relevance. The
contralateral breast also receives some dose using
TOMO and CK, which is not the case using 3D-CRT.
This dose remains however very low (below 2 Gy) and
seems not clinically relevant in literature.
Fiducial implantation is an additional invasive process
for the patients. The first part of this study shows that
tracking surgical clips implanted around the resection
volume during surgery is feasible (positioning accuracy
below 1 mm) given that the clips are large enough to be
observed on digitally reconstructed radiographs (DRR).
Only the larger clips that are available (VITALITEC
Medium-Large) could be tracked in our phantom.
We believe that our results may be obtained with the
vast majority of patients. The phantom density was close
to breast density (0.97 g.cm−3 as opposed to 0.95 g.cm−3
for adipose tissue and 1.02 g.cm−3 for glandular tissue).
The XSight lung phantom was used to accurately repro-
duce the thoracic cage. To reproduce what we believe is
the worst case scenario, the dimensions of our phantom
were chosen to represent the largest breast size mea-
sured on 30 patients, and the target volume was posi-
tioned close to the ribs.
Our comparative dosimetric results strengthen the
previously published work from Xu et al. [11] who
showed the feasibility of using the CyberKnife for APBI.
Their work proposed the dosimetric comparison of
treatment plans calculated for 14 patients to previously
published results obtained using 3D-CRT and IMRT.
However, the results were somewhat limited because the
authors compared their planning results to published
data based on IMRT and 3D-CRT, and they did not in-
vestigate surgical clip tracking. Using different plans cal-
culated on the same patients, we were able to compare
mean DVHs for a better evaluation of the differences be-
tween techniques. To the best of our knowledge, no
other study to date has compared the CyberKnife with
other techniques in this manner.
For each treatment modality, dose calculations were
performed using the more accurate algorithm that was
available in each treatment planning station (type B, tak-
ing into account heterogeneities for secondary electron
transport). For a fairer comparison, it would have been
interesting to compute the dose using the same algo-
rithm for each technique. However, we believe that the
results obtained on NTBTV are too important to be a
result of the dose calculation algorithm. It may also have
been interesting to calculate dose distributions on
4DCTs to investigate further the benefit of tracking. Un-
fortunately, 4DCTs were not available for the selected
patients.
In this study, we compared only the CyberKnife to
tomotherapy and 3D-CRT. Comparisons between
tomotherapy and 3D-CRT have previously been pub-
lished [21, 22]. Because of the strict constraints imposed
by the SHARE protocol, the only significant differences
between tomotherapy and 3D-CRT in our work are lo-
cated in the NTBTV. The direct electron field used in
3D-CRT reduces low doses to the NTBTV compared
with tomotherapy.
The Cyberknife is not the only technical option to track a
moving target. It would be interesting to compare the
tracking accuracy of all available tracking systems and de-
rive the CTV to PTV margins achievable with each system.
However, we believe that these margins would be very close
and that the results we obtained without tracking would be
consistent with the results we would obtain with tracking.
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Conclusion
Tracking and non-coplanar beam directions such as
used with robotic stereotactic radiotherapy in our case
may be used for APBI to more efficiently spare the
NTBTV. This could allow better cosmetic results. This
technique could be offered to patients at a higher risk
for late toxicity after APBI or in whom dosimetric con-
straints cannot be respected with other techniques.
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